News
PMCPA News
Press releases appear below, filter by date.
Comments are invited on proposals to amend Clause 16.3 with regards to representatives examinations.
Merz Pharma, Lilly and Daiichi-Sankyo have each breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry.
Published updates reflect the Second 2012 Edition of the Code.
Following recent changes to the ABPI Code of Practice for the Pharmaceutical Industry, the PMCPA has updated its popular e-learning module and quick guides to the Code.
ProStrakan Group plc, Cephalon UK Limited and GlaxoSmithKline Consumer Healthcare have each breached the ABPI Code of Practice for the Pharmaceutical Industry.
To highlight these breaches, all are the subject of advertisements in the medical, pharmaceutical and nursing press.
The company has brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Thame Laboratories was required to issue a corrective statement to recipients of the letter at issue.
The Prescription Medicines Code of Practice Authority (PMCPA) has now published its public consultation on proposed amendments to the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry.
Sanofi and Otsuka have each breached Clause 2 of the Code and are subject to advertisements in the medical, pharmaceutical and nursing press. In addition Sanofi was publicly reprimanded.
We are seeking to appoint three new independent members to the Code of Practice Appeal Board in 2015.
Consultation launched on proposed changes to the ABPI Code of Practice for the Pharmaceutical Industry and the Constitution and Procedure for the Prescription Medicines Code of Practice Authority.
Astellas Pharmaceuticals Limited will be named in advertisements(1) following breaches of the ABPI Code of Practice for the Pharmaceutical Industry.
Astellas Pharma named in advertisements following breaches of the ABPI Code of Practice.
Bayer Healthcare has breached Clause 2 of the ABPI Code of Practice and is the subject of advertisements in the medical, pharmaceutical and nursing press.